Changing the first Overactive Bladder (OAB) therapy with Tolterodine ER to Fesoterodine in daily practice: The effect of aging on patient-reported treatment benefit in the IMPACTA study

Abstract Category

Detrusor Overactivity

Links
	Abstract 356
	Non Discussion Poster Scientific Non Discussion Poster Session 31
	1. Department of Urology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 2. Department of Gynecology, Hospital de Fuenlabrada, Madrid, Spain, 3. Department of Urology, Hospital General Universitario, Valencia, Spain, 4. Medical Department, Pfizer SLU, 5. Medical Department, Pfizer Inc., 6. HEOR Department, Pfizer SLU
Abstract PDF Edit Abstract Abstract Centre